

GLAXOSMITHKLINE PLC
Form 6-K
July 14, 2010

FORM 6-K

**SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For period ending July 2010

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of an increase in interests in Ordinary shares in GlaxoSmithKline plc purchased at a price of £11.75 per share on 13 July 2010, and

Ordinary share ADRs

in GlaxoSmithKline plc

purchased at a price of \$34.12 per ADR

on 13 July 2010, in respect of the personal holdings of the under-mentioned persons

following the re-investment of the dividend paid to shareholders on 8 July 2010.

| | Ordinary shares | ADRs |
|----------------------|------------------------|-------------|
| Dr M M Slaoui | 159.45 | 159.57 |
| Mrs C E Bruck Slaoui | 32.71 | 5.60 |
| Mr J M Clarke | 401.99 | |
| Mr M Dunoyer | 192.20 | |
| Mr E J Gray | 226.97 | |
| Mr W C Louv | | 124.50 |
| Mr D J Phelan | | 304.25 |
| Dr D Pulman | | 187.24 |
| Mr D S Redfern | 122.89 | |
| Mr J R Stéphenne | 594.80 | |
| Ms C Thomas | 93.02 | |
| Mr P J T Vallance | 55.64 | |

The Company was advised of this information on 14 July 2010.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell
Company Secretary

14 July 2010

SIGNATURES

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: July 14, 2010

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc